BioCentury | Oct 19, 2015
Clinical News

IV finafloxacin: Additional Phase II data

...Agents and Chemotherapy and International Congress of Chemotherapy and Infection joint meeting in San Diego. MerLion...
...TOC visit 17 days after the start of treatment vs. ciprofloxacin (see BioCentury Jan. 19). MerLion Pharmaceuticals Pte. Ltd....
BioCentury | Oct 19, 2015
Clinical News

Oral finafloxacin: Additional Phase II data

...Agents and Chemotherapy and International Congress of Chemotherapy and Infection joint meeting in San Diego. MerLion...
...TOC visit 17 days after the start of treatment vs. ciprofloxacin (see BioCentury Jan. 19). MerLion Pharmaceuticals Pte. Ltd....
BioCentury | Feb 2, 2015
Clinical News

Xtoro topical finafloxacin regulatory update

...Staphylococcus aureus. Xtoro is a pH-activated fluoroquinolone antibiotic. Alcon has exclusive, North American rights from MerLion...
...to develop and commercialize topical finafloxacin to treat ear infections (see BioCentury, Jan. 17, 2011). MerLion Pharmaceuticals Pte. Ltd....
BioCentury | Jan 19, 2015
Clinical News

IV finafloxacin: Phase II data

...oral finafloxacin for the remainder of the 5- or 10-day treatment period. In 12-18 months, MerLion...
...plans to start a Phase III trial evaluating finafloxacin under the same IV-to-oral treatment protocol. MerLion Pharmaceuticals Pte. Ltd....
BioCentury | Jan 19, 2015
Clinical News

Oral finafloxacin: Phase II data

...oral finafloxacin for the remainder of the 5- or 10-day treatment period. In 12-18 months, MerLion...
...plans to start a Phase III trial evaluating finafloxacin under the same IV-to-oral treatment protocol. MerLion Pharmaceuticals Pte. Ltd....
BioCentury | Jan 12, 2015
Finance

Buyside view XXIII: Milestones galore

...Inc. (NYSE:MRK) Belsomra suvorexant Insomnia U.S. Merck & Co. Inc. (NYSE:MRK) Keytruda pembrolizumab Melanoma U.S. MerLion Pharmaceuticals Pte. Ltd./Novartis...
BioCentury | Jun 30, 2014
Clinical News

IV finafloxacin: Completed Phase II enrollment

...ophthalmic unit of Novartis AG (NYSE:NVS; SIX:NOVN, Basel, Switzerland) has exclusive, North American rights from MerLion...
...topical formulation has completed a pair of Phase III trials to treat acute otitis externa. MerLion Pharmaceuticals Pte. Ltd....
BioCentury | Sep 2, 2013
Clinical News

IV and oral finafloxacin regulatory update

...ophthalmic unit of Novartis AG (NYSE:NVS; SIX:NOVN, Basel, Switzerland) received exclusive, North American rights from MerLion...
...to treat acute otitis externa. Novartis acquired Alcon in 2011 (see BioCentury, April 18, 2011). MerLion Pharmaceuticals Pte. Ltd....
BioCentury | Dec 17, 2012
Clinical News

IV finafloxacin: Phase II started

...ophthalmic unit of Novartis AG (NYSE:NVS; SIX:NOVN, Basel, Switzerland) received exclusive, North American rights from MerLion...
...see BioCentury, Jan. 17, 2011). Novartis acquired Alcon last year (see BioCentury, April 18, 2011). MerLion Pharmaceuticals Pte. Ltd....
BioCentury | Dec 17, 2012
Clinical News

Oral finafloxacin: Phase II started

...ophthalmic unit of Novartis AG (NYSE:NVS; SIX:NOVN, Basel, Switzerland) received exclusive, North American rights from MerLion...
...see BioCentury, Jan. 17, 2011). Novartis acquired Alcon last year (see BioCentury, April 18, 2011). MerLion Pharmaceuticals Pte. Ltd....
Items per page:
1 - 10 of 65
BioCentury | Oct 19, 2015
Clinical News

IV finafloxacin: Additional Phase II data

...Agents and Chemotherapy and International Congress of Chemotherapy and Infection joint meeting in San Diego. MerLion...
...TOC visit 17 days after the start of treatment vs. ciprofloxacin (see BioCentury Jan. 19). MerLion Pharmaceuticals Pte. Ltd....
BioCentury | Oct 19, 2015
Clinical News

Oral finafloxacin: Additional Phase II data

...Agents and Chemotherapy and International Congress of Chemotherapy and Infection joint meeting in San Diego. MerLion...
...TOC visit 17 days after the start of treatment vs. ciprofloxacin (see BioCentury Jan. 19). MerLion Pharmaceuticals Pte. Ltd....
BioCentury | Feb 2, 2015
Clinical News

Xtoro topical finafloxacin regulatory update

...Staphylococcus aureus. Xtoro is a pH-activated fluoroquinolone antibiotic. Alcon has exclusive, North American rights from MerLion...
...to develop and commercialize topical finafloxacin to treat ear infections (see BioCentury, Jan. 17, 2011). MerLion Pharmaceuticals Pte. Ltd....
BioCentury | Jan 19, 2015
Clinical News

IV finafloxacin: Phase II data

...oral finafloxacin for the remainder of the 5- or 10-day treatment period. In 12-18 months, MerLion...
...plans to start a Phase III trial evaluating finafloxacin under the same IV-to-oral treatment protocol. MerLion Pharmaceuticals Pte. Ltd....
BioCentury | Jan 19, 2015
Clinical News

Oral finafloxacin: Phase II data

...oral finafloxacin for the remainder of the 5- or 10-day treatment period. In 12-18 months, MerLion...
...plans to start a Phase III trial evaluating finafloxacin under the same IV-to-oral treatment protocol. MerLion Pharmaceuticals Pte. Ltd....
BioCentury | Jan 12, 2015
Finance

Buyside view XXIII: Milestones galore

...Inc. (NYSE:MRK) Belsomra suvorexant Insomnia U.S. Merck & Co. Inc. (NYSE:MRK) Keytruda pembrolizumab Melanoma U.S. MerLion Pharmaceuticals Pte. Ltd./Novartis...
BioCentury | Jun 30, 2014
Clinical News

IV finafloxacin: Completed Phase II enrollment

...ophthalmic unit of Novartis AG (NYSE:NVS; SIX:NOVN, Basel, Switzerland) has exclusive, North American rights from MerLion...
...topical formulation has completed a pair of Phase III trials to treat acute otitis externa. MerLion Pharmaceuticals Pte. Ltd....
BioCentury | Sep 2, 2013
Clinical News

IV and oral finafloxacin regulatory update

...ophthalmic unit of Novartis AG (NYSE:NVS; SIX:NOVN, Basel, Switzerland) received exclusive, North American rights from MerLion...
...to treat acute otitis externa. Novartis acquired Alcon in 2011 (see BioCentury, April 18, 2011). MerLion Pharmaceuticals Pte. Ltd....
BioCentury | Dec 17, 2012
Clinical News

IV finafloxacin: Phase II started

...ophthalmic unit of Novartis AG (NYSE:NVS; SIX:NOVN, Basel, Switzerland) received exclusive, North American rights from MerLion...
...see BioCentury, Jan. 17, 2011). Novartis acquired Alcon last year (see BioCentury, April 18, 2011). MerLion Pharmaceuticals Pte. Ltd....
BioCentury | Dec 17, 2012
Clinical News

Oral finafloxacin: Phase II started

...ophthalmic unit of Novartis AG (NYSE:NVS; SIX:NOVN, Basel, Switzerland) received exclusive, North American rights from MerLion...
...see BioCentury, Jan. 17, 2011). Novartis acquired Alcon last year (see BioCentury, April 18, 2011). MerLion Pharmaceuticals Pte. Ltd....
Items per page:
1 - 10 of 65